President Trump called Vladimir Putin “my friend” on Thursday at a summit in China that The New York Times described as the first of its kind for the three leaders.
Trump, Xi Jinping and Putin met face to face for the first time in that configuration, near the end of Trump’s whirlwind trip through Asia.
“It’s an honor to be with you. You’re my friend, and we have a very special relationship. And I think as long as you and I are in charge of things, we’ll never have a problem,” Trump said of Putin.
The warm language carried over from Trump’s stop in Beijing, where Xi welcomed him with a red carpet at the airport and a hug on the tarmac.
The Times reported that Trump does not plan to raise the spying scandal that engulfed NVIDIA, the most high-profile dispute between Washington and Beijing right now. Instead, he is expected to try to smooth over economic tensions and keep the trade war from flaring back up.
Putin gets his stage
The summit mattered most for Putin, according to Paul Sonne, The Times’ Moscow bureau chief, who reported from the meeting that Putin himself pushed for.
The Russian president used the moment to declare that efforts to isolate his country after the invasion of Ukraine have failed — and the image of him standing beside the two most powerful leaders in the world proved the point. Trump has invited Putin to keep the momentum going at the G20 summit in Miami next month.
Sonne offered two explanations for why Trump has worked so hard to bring Putin back into the fold. “I think the generous explanation is that he thought he could use his friendliness with Putin to try to end the war in Ukraine,” Sonne said.
“He came back into office saying that he would end the war in 24 hours. But nearly two years into his second term, in many ways, negotiations are still at the starting line.”
“I think the less generous explanation is that Trump personally has an affinity for authoritarian rule,” Sonne added. “He sees something he likes in Vladimir Putin and Xi Jinping.”
GLP-1s reach younger children
On the health front, a number that has been building for a decade now has a new data point attached to it. About 15 percent of American adults say they have used a GLP-1 weight-loss drug, according to a recent Gallup survey.
This week, a closely watched clinical trial extended the story to children: kids age 6 to 11, many with severe obesity, took a GLP-1 for about a year and a half, and nearly 40 percent of them no longer had obesity.
The drugmaker behind Ozempic and Wegovy plans to ask the Food and Drug Administration to approve the medication for children 6 to 11. It is already approved for those 12 and up.
“I spoke to almost a dozen doctors, and they all agree that pediatric obesity is a massive problem and we need to be doing more to address it. But the question is whether the risks outweigh the benefits for these medications. And people are really deeply divided,” said Dani Blum, a health reporter for The New York Times.
The divide runs along a clear line. Supporters argue that for severely obese children, no tool this powerful has existed before, and that intervening early could head off complications that follow a child for life. Skeptics point to open questions about how the drugs could affect puberty, growth and height at ages when proper nutrition is critical.
Putin, born in 1952 in Leningrad, now Saint Petersburg, spent 16 years as a KGB foreign intelligence officer, rising to the rank of lieutenant colonel before resigning in 1991 to enter politics in his home city. He moved to Moscow in 1996, was appointed prime minister in August 1999, and became acting president after the resignation of Boris Yeltsin, winning his first term in March 2000.
He has remained Russia’s dominant figure since 1999, serving as prime minister from 2008 to 2012 before returning to the presidency. In 2021, he signed constitutional amendments allowing him to run for reelection twice more, potentially extending his presidency to 2036.
“When you’re talking about ages 6 through 12, that’s when your bones are developing. That’s when you’re growing. And these are medications that obliterate your appetite,” Blum said. MyNews, which also covered the story, notes that GLP-1 receptor agonists are a class of medications typically used to treat type 2 diabetes, with weight management in children a newer frontier.
- Bogalusa Bookkeeper Pleads Guilty to Embezzling Over $200,000
- Río Negro’s Línea 102 to Staff Family Zones at First Sol Corre Night Race
- Inter Miami host Columbus Crew in 2026 MLS Cup Playoffs Game 1 (world-today-journal.com)
- Judge Orders Trump Administration to Release Law Firm Deal Records (time.news)